Martinez, Xochiquetzal U.
Chowdhury, Arnab
Stiller, Tracey
Palmer, Joycelynne
Loscalzo, Matthew
Barrios, Estella
Abdulla, Farah R.
Zain, Jasmine
Rosen, Steven T.
Querfeld, Christiane
Funding for this research was provided by:
National Institutes of Health (P30CA033572, R01 CA229510-01)
Leukemia and Lymphoma Society (2325-19)
Article History
Received: 5 June 2020
Accepted: 20 April 2021
First Online: 7 May 2021
Declarations
:
: The study was exempt from IRB review under 45CFR46.104 (d), and consent was not required. The study was approved for a Waiver of HIPAA Authorization (45CFR164.512(i)(2)(ii)).
: Not applicable.
: Not applicable.
: X.U.M., A.C., T.S., E.B.: none. J.P.: statistical consultant to Gilead Sciences; statistics instructor for ASTCT. M.L.: consultant to AstraZeneca. F.R.A.: consultant to Mallinckrodt; speaker’s bureau for Mallinckrodt; receives grant/research support from Johnson & Johnson, Elorac, Trillium, Stemline, MiRagen, Bioniz, and Mallinckrodt. J.Z.: consultant to Kyowa Kirin, Seattle Genetics, and Mundi Pharma. S.T.R.: speaker’s bureau for Celgene, Global Education Group and Paradigm Medical Communications, LLC, and Abbvie; consultant to Novartis Pharmaceuticals Corporation, Pepromene Bio, Inc, Exicure, and Apobiologix/Apotex Inc.; education advisory board to Seattle Genetics, NeoGenomics, and Aileron Therapeutics, Inc; has stock options with Pepromene Bio, Inc, and Exicure. C.Q<u>.</u>: Consultant to MiRagen, Helsinn/Actelion, Medvir, Stemline Therapeutics, Trillium, Bioniz, and Kyowa Kirin; contracted clinical investigator/researcher to MiRagen, Helsinn/Actelion, Bioniz, Kyowa Kirin, Celgene, Trillium, Esai, Soligenix, and Elorac; received research grant from Celgene.